Skip to main content

Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours

Abstract

The fourth edition of the World Health Organization (WHO) classification of endocrine tumours contains substantial new findings for the adrenal tumours. The tumours are presented in two chapters labelled as “Tumours of the adrenal cortex” and “Tumours of the adrenal medulla and extra-adrenal paraganglia.” Tumours of the adrenal cortex are classified as cortical carcinoma, cortical adenoma, sex cord stromal tumours, adenomatoid tumour, mesenchymal and stromal tumours (myelolipoma and schwannoma), haematological tumours, and secondary tumours. Amongst them, schwannoma and haematological tumours are newly documented. The major updates in adrenal cortical lesions are noted in the genetics of the cortical carcinoma and cortical adenoma based on the data from The Cancer Genome Atlas (TCGA). Also, a system for differentiation of oncocytoma from oncocytic cortical carcinoma is adopted. Tumours of the adrenal medulla and extra-adrenal paraganglia comprise pheochromocytoma, paraganglioma (head and neck paraganglioma and sympathetic paraganglioma), neuroblastic tumours (neuroblastoma, nodular ganglioneuroblastoma, intermixed ganglioneuroblastoma, and ganglioneuroma), composite pheochromocytoma, and composite paraganglioma. In this group, neuroblastic tumours are newly included in the classification. The clinical features, histology, associated pathologies, genetics, and predictive factors of pheochromocytoma and paraganglioma are the main changes introduced in this chapter of WHO classification of endocrine tumours. The term “metastatic pheochromocytoma/paraganglioma” is used to replace “malignant pheochromocytoma/paraganglioma.” Also, composite pheochromocytoma and composite paraganglioma are now documented in separate sections instead of one. Overall, the new classification incorporated new data on pathology, clinical behaviour, and genetics of the adrenal tumours that are important for current management of patients with these tumours.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10

References

  1. Lloyd RV, Osamura RY, Kloppel G, Rosai J. WHO classification of tumours: pathology and genetics of tumours of endocrine organs. 4th ed. Lyon: IARC; 2017.

    Google Scholar 

  2. DeLellis RA, Lloyd RV, Heitz PU, Eng C. WHO classification of tumours: pathology and genetics of tumours of endocrine organs. 3rd ed. Lyon: IARC; 2004.

    Google Scholar 

  3. Lam KY. Adrenal tumors in Chinese. Virchows Arch A 421:13–16, 1992.

    CAS  Article  Google Scholar 

  4. Pinto EM, Chen X, Easton J, Finkelstein D, Liu Z, Pounds S, Rodriguez-Galindo C, Lund TC, Mardis ER, Wilson RK, Boggs K, Yergeau D, Cheng J, Mulder HL, Manne J, Jenkins J, Mastellaro MJ, Figueiredo BC, Dyer MA, Pappo A, Zhang J, Downing JR, Ribeiro RC, Zambetti GP. Genomic landscape of paediatric adrenocortical tumours. Nat Commun 6: 6302, 2015.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  5. Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario AM, Else T, Knijnenburg TA, Ciriello G, Kim S, Assie G, Morozova O, Akbani R, Shih J, Hoadley KA, Choueiri TK, Waldmann J, Mete O, Robertson AG, Wu HT, Raphael BJ, Shao L, Meyerson M, Demeure MJ, Beuschlein F, Gill AJ, Sidhu SB, Almeida MQ, Fragoso MC, Cope LM, Kebebew E, Habra MA, Whitsett TG, Bussey KJ, Rainey WE, Asa SL, Bertherat J, Fassnacht M, Wheeler DA; Cancer Genome Atlas Research Network., Hammer GD, Giordano TJ, Verhaak RG. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell 29: 723–736, 2016.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  6. Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario AM, Else T, Knijnenburg TA, Ciriello G, Kim S, Assie G, Morozova O, Akbani R, Shih J, Hoadley KA, Choueiri TK, Waldmann J, Mete O, Robertson AG, Wu HT, Raphael BJ, Shao L, Meyerson M, Demeure MJ, Beuschlein F, Gill AJ, Sidhu SB, Almeida MQ, Fragoso MC, Cope LM, Kebebew E, Habra MA, Whitsett TG, Bussey KJ, Rainey WE, Asa SL, Bertherat J, Fassnacht M, Wheeler DA; Cancer Genome Atlas Research Network., Hammer GD, Giordano TJ, Verhaak RG. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 30: 363, 2016.

    CAS  PubMed  Article  Google Scholar 

  7. Assié G, Letouzé E, Fassnacht M, Jouinot A, Luscap W, Barreau O, Omeiri H, Rodriguez S, Perlemoine K, René-Corail F, Elarouci N, Sbiera S, Kroiss M, Allolio B, Waldmann J, Quinkler M, Mannelli M, Mantero F, Papathomas T, De Krijger R, Tabarin A, Kerlan V, Baudin E, Tissier F, Dousset B, Groussin L, Amar L, Clauser E, Bertagna X, Ragazzon B, Beuschlein F, Libé R, de Reyniès A, Bertherat J. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet 46: 607–612, 2014.

    PubMed  Article  CAS  Google Scholar 

  8. Assié G, Jouinot A, Bertherat J. The “omics” of adrenocortical tumours for personalized medicine. Nat Rev Endocrinol 10: 215–228, 2014.

    PubMed  Article  CAS  Google Scholar 

  9. Dworakowska D, Drabarek A, Wenzel I, Babińska A, Świątkowska-Stodulska R, Sworczak K. Adrenocortical cancer (ACC)—literature overview and own experience. Endokrynol Pol 65: 492–502, 2014

    PubMed  Article  Google Scholar 

  10. Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, Budäus L, Shariat SF, Guazzoni G, Montorsi F, Karakiewicz PI. The European network for the study of adrenal tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer 46: 713–719, 2010.

    PubMed  Article  Google Scholar 

  11. Straka M, Soumarova R, Bulejcik J, Banik M, Pura M, Skrovina M. Giant adrenocortical carcinoma with 27-month disease-free survival by surgical resection alone: a case report. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 158: 474–478, 2014.

    PubMed  Google Scholar 

  12. Papotti M, Libè R, Duregon E, Volante M, Bertherat J, Tissier F. The Weiss score and beyond—histopathology for adrenocortical carcinoma. Horm Cancer. 2: 333–340, 2011.

    CAS  PubMed  Article  Google Scholar 

  13. Libé R, Borget I, Ronchi CL, Zaggia B, Kroiss M, Kerkhofs T, Bertherat J, Volante M, Quinkler M, Chabre O, Bala M, Tabarin A, Beuschlein F, Vezzosi D, Deutschbein T, Borson-Chazot F, Hermsen I, Stell A, Fottner C, Leboulleux S, Hahner S, Mannelli M, Berruti A, Haak H, Terzolo M, Fassnacht M, Baudin E ENSAT network. Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): a European Network for the Study of Adrenal Tumor (ENSAT) study. Ann Oncol 26: 2119–2125, 2015.

    PubMed  Article  Google Scholar 

  14. Beuschlein F, Weigel J, Saeger W, Kroiss M, Wild V, Daffara F, Libé R, Ardito A, Al Ghuzlan A, Quinkler M, Oßwald A, Ronchi CL, de Krijger R, Feelders RA, Waldmann J, Willenberg HS, Deutschbein T, Stell A, Reincke M, Papotti M, Baudin E, Tissier F, Haak HR, Loli P, Terzolo M, Allolio B, Müller HH, Fassnacht M. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab 100: 841–849, 2015.

    CAS  PubMed  Article  Google Scholar 

  15. Duregon E, Molinaro L, Volante M, Ventura L, Righi L, Bolla S, Terzolo M, Sapino A, Papotti MG. Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma. Mod Pathol 27: 1246–1254, 2014.

    CAS  PubMed  Article  Google Scholar 

  16. Lam KY, Wat MS. Adrenal cortical black adenoma: report of two cases and review of the literature. J Urol Pathol 4: 183–190, 1996.

    Google Scholar 

  17. Mearini L, Del Sordo R, Costantini E, Nunzi E, Porena M. Adrenal oncocytic neoplasm: a systematic review. Urol Int 91: 125–133, 2013.

    CAS  PubMed  Article  Google Scholar 

  18. Nakamura Y, Yamazaki Y, Tezuka Y, Satoh F, Sasano H. Expression of CYP11B2 in aldosterone-producing adrenocortical adenoma: regulatory mechanisms and clinical significance. Tohoku J Exp Med 240:183–190, 2016.

    PubMed  Article  Google Scholar 

  19. Thiel A, Reis AC, Haase M, Goh G, Schott M, Willenberg HS, Scholl UI. PRKACA mutations in cortisol-producing adenomas and adrenal hyperplasia: a single-center study of 60 cases. Eur J Endocrinol 172: 677–685, 2015.

    CAS  PubMed  Article  Google Scholar 

  20. Azevedo MF, Stratakis CA. The transcriptome that mediates increased cyclic adenosine monophosphate signaling in PRKAR1A defects and other settings. Endocr Pract. 17S3: 2–7, 2011.

    Article  Google Scholar 

  21. Bonnet S, Gaujoux S, Launay P, Baudry C, Chokri I, Ragazzon B, Libé R, René-Corail F, Audebourg A, Vacher-Lavenu MC, Groussin L, Bertagna X, Dousset B, Bertherat J, Tissier F. Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors. J Clin Endocrinol Metab 96: E419-E426, 2011.

    CAS  PubMed  Article  Google Scholar 

  22. Orselli RC, Bassler TJ. Theca granuloma cell tumor arising in adrenal. Cancer 31: 474–477, 1973

    CAS  PubMed  Article  Google Scholar 

  23. Trost BN, Koenig MP, Zimmermann A, Zachmann M, Müller J. Virilization of a post-menopausal woman by a testosterone-secreting Leydig cell type adrenal adenoma. Acta Endocrinol (Copenh). 98: 274–282, 1981

    CAS  Google Scholar 

  24. Vasiloff J, Chideckel EW, Boyd CB, Foshag LJ. Testosterone-secreting adrenal adenoma containing crystalloids characteristic of Leydig cells. Am J Med 79: 772–776, 1985.

    CAS  PubMed  Article  Google Scholar 

  25. Pollock WJ, McConnell CF, Hilton C, Lavine RL. Virilizing Leydig cell adenoma of adrenal gland. Am J Surg Pathol. 10: 816–822, 1986.

    CAS  PubMed  Article  Google Scholar 

  26. Hameed A, Coleman RL. Fine-needle aspiration cytology of primary granulosa cell tumor of the adrenal gland: a case report. Diagn Cytopathol. 22: 107–109, 2000.

    CAS  PubMed  Article  Google Scholar 

  27. Cheng JY, Gill AJ, Kumar SK. Granulosa cell tumour of the adrenal. Pathology 47: 487–489, 2015.

    PubMed  Article  Google Scholar 

  28. Simpson PR. Adenomatoid tumor of the adrenal gland. Arch Pathol Lab Med 114: 725–727, 1990.

    CAS  PubMed  Google Scholar 

  29. El-Daly H, Rao P, Palazzo F, Gudi M. A rare entity of an unusual site: adenomatoid tumour of the adrenal gland: a case report and review of the literature. Patholog Res Int. 2010: 702472, 2010.

    Google Scholar 

  30. Taskin OC, Gucer H, Mete O. An unusual adrenal cortical nodule: composite adrenal cortical adenoma and adenomatoid tumor. Endocr Pathol 26: 370–373, 2015.

    PubMed  Article  Google Scholar 

  31. Timonera ER, Paiva ME, Lopes JM, Eloy C, van der Kwast T, Asa SL. Composite adenomatoid tumor and myelolipoma of adrenal gland: report of 2 cases. Arch Pathol Lab Med. 132: 265–267, 2008.

    PubMed  Google Scholar 

  32. Kenney PJ, Wagner BJ, Rao P, Heffess CS. Myelolipoma: CT and pathologic features. Radiology 208:87–95, 1998

    CAS  PubMed  Article  Google Scholar 

  33. Mitsui Y, Yasumoto H, Hiraki M, Arichi N, Ishikawa N, Harada Y, Maruyama R, Shiina H. Coordination of bone morphogenetic protein 2 (BMP2) and aberrant canonical Wnt/β-catenin signaling for heterotopic bone formation in adrenal myelolipoma: a case report. Can Urol Assoc J 8: E104–E107, 2014.

    PubMed  PubMed Central  Article  Google Scholar 

  34. Lam A. Lipomatous tumours in adrenal gland: WHO updates and clinical implications Endocr Relat Cancer 24: R65-R79, 2017

    PubMed  Article  Google Scholar 

  35. Khong PL, Lam KY, Ooi GC, Liu MJ, Metreweli C. Mature teratomas of the adrenal gland: imaging features. Abdom Imagining 2002; 27: 347–350.

    CAS  Article  Google Scholar 

  36. Lam KY, Lo CY. Adrenal lipomatous tumours: a 30 year clinicopathological experience at a single institution. J Clin Pathol 54: 707–712, 2001.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  37. Lam KY, Lo CY. Teratoma in the region of adrenal gland: a unique entity masquerading as lipomatous adrenal tumor. Surgery 126: 90–94, 1999.

    CAS  PubMed  Article  Google Scholar 

  38. Lam KY, Chan ACL, Ng IOL. Giant adrenal lipoma: a report of two cases and review of the literature. Scand J Urol Nephrol 31:89–90, 1997.

    CAS  PubMed  Article  Google Scholar 

  39. Au WY, Tam PC, Ma SK, Lam KY. Giant myelolipoma in a patient with thalassemia intermedia. Am J Hematol 65: 265–266, 2000.

    CAS  PubMed  Article  Google Scholar 

  40. Zhao J, Sun F, Jing X, Zhou W, Huang X, Wang H, Zhu Y, Yuan F, Shen Z. The diagnosis and treatment of primary adrenal lipomatous tumours in Chinese patients: a 31-year follow-up study. Can Urol Assoc J 8: E132-E136, 2014.

    PubMed  PubMed Central  Article  Google Scholar 

  41. Shenoy VG, Thota A, Shankar R, Desai MG. Adrenal myelolipoma: controversies in its management. Indian J Urol 31: 94–101, 2015.

    PubMed  PubMed Central  Article  Google Scholar 

  42. Li SQ, Zhang YS, Shi J, Li HZ. Clinical features and retroperitoneal laparoscopic resection of adrenal schwannoma in 19 patients. Endocr Pract 21: 323–329, 2015.

    PubMed  Article  Google Scholar 

  43. Mohiuddin Y, Gilliland MG. Adrenal schwannoma: a rare type of adrenal incidentaloma. Arch Pathol Lab Med 137: 1009–1014, 2013.

    PubMed  Article  Google Scholar 

  44. Xiao C, Xu B, Ye H, Yang Q, Wang L, Sun YH. Experience with adrenal schwannoma in a Chinese population of six patients. J Endocrinol Invest 34: 417–421, 2011.

    CAS  PubMed  Article  Google Scholar 

  45. Rashidi A, Fisher SI. Primary adrenal lymphoma: a systematic review. Ann Hematol 92: 1583–1593, 2013

    CAS  PubMed  Article  Google Scholar 

  46. Mozos A, Ye H, Chuang WY, Chu JS, Huang WT, Chen HK, Hsu YH, Bacon CM, Du MQ, Campo E, Chuang SS. Most primary adrenal lymphomas are diffuse large B-cell lymphomas with non-germinal center B-cell phenotype, BCL6 gene rearrangement and poor prognosis. Mod Pathol 22: 1210–1217, 2009.

    CAS  PubMed  Article  Google Scholar 

  47. Lam KY, Lo CY. Metastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital. Clin Endocrinol 56: 95–101, 2002.

    Article  Google Scholar 

  48. Gryn A, Peyronnet B, Manunta A, Beauval JB, Bounasr E, Nouhaud FX, Rioux-Leclercq N, Caron P, Thoulouzan M, Verhoest G, Soulie M, Bensalah K, Huyghe E. Patient selection for laparoscopic excision of adrenal metastases: a multicenter cohort study. Int J Surg 24: 75–80, 2015.

    PubMed  Article  Google Scholar 

  49. Pillai S, Gopalan V, Lo CY, Liew V, Smith RA, Lam AK. Silent genetic alterations identified by targeted next-generation sequencing in pheochromocytoma/paraganglioma: a clinicopathological correlations. Exp Mol Pathol. 102: 41–46, 2017.

  50. Pillai S, Gopalan V, Smith RA, Lam AK. Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era. Crit Rev Oncol Hematol 100: 190–208, 2016.

  51. Lam AK. Update on paragangliomas and pheochromocytomas. Turk Patoloji Derg 31S1: 105–112, 2015.

  52. Burnichon N, Buffet A, Parfait B, Letouzé E, Laurendeau I, Loriot C, Pasmant E, Abermil N, Valeyrie-Allanore L, Bertherat J, Amar L, Vidaud D, Favier J, Gimenez-Roqueplo AP. Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Hum Mol Genet 21: 5397–5405, 2012.

    CAS  PubMed  Article  Google Scholar 

  53. Niemeijer ND, Papathomas TG, Korpershoek E, de Krijger RR, Oudijk L, Morreau H, Bayley JP, Hes FJ, Jansen JC, Dinjens WN, Corssmit EP. Succinate dehydrogenase (SDH)-deficient pancreatic neuroendocrine tumor expands the SDH-related tumor spectrum. J Clin Endocrinol Metab. 2015; 100: E1386–E1393.

    CAS  PubMed  Article  Google Scholar 

  54. Toledo SP, Lourenço DM Jr, Sekiya T, Lucon AM, Baena ME, Castro CC, Bortolotto LA, Zerbini MC, Siqueira SA, Toledo RA, Dahia PL. Penetrance and clinical features of pheochromocytoma in a six-generation family carrying a germline TMEM127 mutation. J Clin Endocrinol Metab 100: E308-E318, 2015.

    CAS  PubMed  Article  Google Scholar 

  55. Hoekstra AS, Devilee P, Bayley JP. Models of parent-of-origin tumorigenesis in hereditary paraganglioma. Semin Cell Dev Biol 43:117–124, 2015.

    PubMed  Article  Google Scholar 

  56. Thompson LD. Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 26: 551–566, 2002.

    PubMed  Article  Google Scholar 

  57. Agarwal A, Mehrotra PK, Jain M, Gupta SK, Mishra A, Chand G, Agarwal G, Verma AK, Mishra SK, Singh U. Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy? World J Surg 34:3022–3028, 2010.

    PubMed  Article  Google Scholar 

  58. Mlika M, Kourda N, Zorgati MM, Bahri S, Ben Ammar S, Zermani R. Prognostic value of pheochromocytoma of the adrenal gland scaled score (PASS score) tests to separate benign from malignant neoplasms. Tunis Med 91: 209–215, 2013.

    PubMed  Google Scholar 

  59. Kimura N, Watanabe T, Noshiro T, Shizawa S and Miura Y. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol 16: 23–32, 2005.

    PubMed  Article  Google Scholar 

  60. Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, Kakoi N, Rakugi H, Ikeda Y, Tanabe A, Nigawara T, Ito S, Kimura I, Naruse M; Phaeochromocytoma Study Group in Japan. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer 21:405–414, 2014.

    PubMed  Article  CAS  Google Scholar 

  61. Kimura N, Takekoshi K, Horii A, Morimoto R, Imai T, Oki Y, Saito T, Midorikawa S, Arao T, Sugisawa C, Yamada M, Otuka Y, Kurihara I, Sugano K, Nakane M, Fukuuchi A, Kitamoto T, Saito J, Nishikawa T, Naruse M. Clinicopathological study of SDHB mutation-related pheochromocytoma and sympathetic paraganglioma. Endocr Relat Cancer. 21: L13–L16, 2014.

    CAS  PubMed  Article  Google Scholar 

  62. Parenti G, Zampetti B, Rapizzi E, Ercolino T, Giachè V, Mannelli M. Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma. J Oncol 2012: 872713, 2012.

    PubMed  PubMed Central  Article  Google Scholar 

  63. Castro-Vega LJ, Letouzé E, Burnichon N, Buffet A, Disderot PH, Khalifa E, Loriot C, Elarouci N, Morin A, Menara M, Lepoutre-Lussey C, Badoual C, Sibony M, Dousset B, Libé R, Zinzindohoue F, Plouin PF, Bertherat J, Amar L, de Reyniès A, Favier J, Gimenez-Roqueplo AP. Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nat Commun. 6: 6044, 2015.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  64. Patterson E, Webb R, Weisbrod A, Bian B, He M, Zhang L, Holloway AK, KrishnaR, Nilubol N, Pacak K, Kebebew E. The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma. Endocr Relat Cancer 19: 157–166, 2012.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  65. Lam KY, Chan ACL, Wong WM, Lam KSL. A review of clinicopathologic features of pheochromocytomas in Hong Kong Chinese. Eur J Surg Oncol 19: 421–427, 1993.

    CAS  PubMed  Google Scholar 

  66. Eisenhofer G, Pacak K, Huynh TT, Qin N, Bratslavsky G, Linehan WM, Mannelli M, Friberg P, Grebe SK, Timmers HJ, Bornstein SR, Lenders JW. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr Relat Cancer 18: 97–111, 2010.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  67. Eisenhofer G, Peitzsch M. Laboratory evaluation of pheochromocytoma and paraganglioma. Clin Chem 60:1486–1499, 2014.

    CAS  PubMed  Article  Google Scholar 

  68. Eisenhofer G, Goldstein DS, Kopin IJ, Crout JR. Pheochromocytoma: rediscovery as a catecholamine-metabolizing tumor. Endocr Pathol 14:193–212, 2003.

    CAS  PubMed  Article  Google Scholar 

  69. Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 56: 331–349, 2004.

    CAS  PubMed  Article  Google Scholar 

  70. Eisenhofer G, Lenders JW, Siegert G, Bornstein SR, Friberg P, Milosevic D, Mannelli M, Linehan WM, Adams K, Timmers HJ, Pacak K. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer 48: 1739–1749, 2012.

    CAS  PubMed  Article  Google Scholar 

  71. Eisenhofer G, Lenders JW, Timmers H, Mannelli M, Grebe SK, Hofbauer LC, Bornstein SR, Tiebel O, Adams K, Bratslavsky G, Linehan WM, Pacak K. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem 57: 411–420, 2011.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  72. Kakkar A, Kaur K, Kumar T, Cherian LB, Kaushal R, Sharma MC, Dhar A, Seth A, Jain D. Pigmented pheochromocytoma: an unusual variant of a common tumor. Endocr Pathol. 27: 42–45, 2016.

    PubMed  Article  Google Scholar 

  73. Kasem K, Lam AK. Adrenal oncocytic phaeochromocytoma with putative adverse histologic features: a unique case report and review of the literature. Endocr Pathol 25: 416–421, 2014.

    PubMed  Article  Google Scholar 

  74. Kim KY, Kim JH, Hong AR, Seong MW, Lee KE, Kim SJ, Kim SW, Shin CS, Kim SY. Disentangling of malignancy from benign pheochromocytomas/paragangliomas. PLoS One 11: e0168413, 2016.

    PubMed  PubMed Central  Article  Google Scholar 

  75. Lam KY, Lo CY, Wat NMS, Luk JM, Lam KSL. The clinicopathological features and importance of p53, Rb and mdm2 expression in phaeochromocytomas and paragangliomas. J Clin Pathol 54:443–448, 2001.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  76. Lam KY, Chan ACL. Paragangliomas: a comparative clinical, histologic and immunohistochemical study. Int J Surg Pathol 1:111–116, 1993.

    Article  Google Scholar 

  77. Chan JKC, Kimura N, Capella C, Gill A, Komminoth P, Lam AKY, Tischler AS, Williams MD. Paraganglion tumours. In: WHO classification of head and neck tumours. El-Nigger AK, Chan JKC, Grandis JF, Takata T, Slootweg PJ (eds), Chapter 10. 4th ed. Lyon: IARC; 2017 pp275–284.

  78. Sajid MS, Hamilton G, Baker DM; Joint Vascular Research Group. A multicenter review of carotid body tumour management. Eur J Vasc Endovasc Surg 34:127–130, 2007.

    CAS  PubMed  Article  Google Scholar 

  79. Piccini V, Rapizzi E, Bacca A, Di Trapani G, Pulli R, Giachè V, Zampetti B, Lucci-Cordisco E, Canu L, Corsini E, Faggiano A, Deiana L, Carrara D, Tantardini V, Mariotti S, Ambrosio MR, Zatelli MC, Parenti G, Colao A, Pratesi C, Bernini G, Ercolino T, Mannelli M. Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients. Endocr Relat Cancer 19:149–155, 2012.

    CAS  PubMed  Article  Google Scholar 

  80. Lam KY, Chan ACL. Paraganglioma of urinary bladder: an immunohistochemical study and report of an unusual association with intestinal carcinoid. Aust NZ J Surg 63: 740–745, 1993.

    CAS  Article  Google Scholar 

  81. Garg A, Mishra D, Bansal M, Maharia HR, Goyal V. Right atrial paraganglioma: an extremely rare primary cardiac neoplasm mimicking myxoma. J Cardiovasc Ultrasound 24: 334–336, 2016.

    PubMed  PubMed Central  Article  Google Scholar 

  82. Michałowska I, Ćwikła J, Prejbisz A, Kwiatek P, Szperl M, Michalski W, Wyrwicz L, Kuśmierczyk M, Januszewicz A, Maciejczyk A, Roszczynko M, Pęczkowska M. Mediastinal paragangliomas related to SDHx gene mutations. Kardiochir Torakochirurgia Pol 13:276–282, 2016.

    PubMed  PubMed Central  Google Scholar 

  83. Soomro NH, Zahid AB, Zafar AA. Non-functional paraganglioma of the mediastinum. J Pak Med Assoc 66: 609–611, 2016.

    PubMed  Google Scholar 

  84. Blanchet EM, Martucci V, Pacak K. Pheochromocytoma and paraganglioma: current functional and future molecular imaging. Front Oncol. 2012 1: 58, 2012.

    PubMed  PubMed Central  Article  Google Scholar 

  85. Blumenfeld J, Cohen N, Anwar M, Teitelman G, Laragh JH, Ruggiero DA. Hypertension and a tumor of the glomus jugulare region. Evidence for epinephrine biosynthesis. Am J Hypertens 6: 382–387, 1993.

    CAS  PubMed  Article  Google Scholar 

  86. Waguespack SG, Rich T, Grubbs E, Ying AK, Perrier ND, Ayala-Ramirez M, Jimenez C. A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 95: 2023–2037, 2010.

    CAS  PubMed  Article  Google Scholar 

  87. Assadipour Y, Sadowski SM, Alimchandani M, Quezado M, Steinberg SM, Nilubol N, Patel D, Prodanov T, Pacak K, Kebebew E. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma. Surgery 161: 230–239, 2017.

    PubMed  Article  Google Scholar 

  88. Mehdiabadi GB, Arab E, Rafsanjani KA, Ansari S, Moinzadeh AM. Neuroblastoma in Iran: an experience of 32 years at a referral children’s hospital. Asian Pac J Cancer Prev 14: 2739–2742, 2013.

    PubMed  Article  Google Scholar 

  89. Cotterill SJ, Pearson AD, Pritchard J, Foot AB, Roald B, Kohler JA, Imeson J. Clinical prognostic factors in 1277 patients with neuroblastoma: results of the European Neuroblastoma Study Group “Survey” 1982–1992. Eur J Cancer 36: 901–908, 2000.

    CAS  PubMed  Article  Google Scholar 

  90. Spinelli C, Rossi L, Barbetta A, Ugolini C, Strambi S. Incidental ganglioneuromas: a presentation of 14 surgical cases and literature review. J Endocrinol Invest 38: 547–554, 2015.

    CAS  PubMed  Article  Google Scholar 

  91. Bielle F, Fréneaux P, Jeanne-Pasquier C, Maran-Gonzalez A, Rousseau A, Lamant L, Paris R, Pierron G, Nicolas AV, Sastre-Garau X, Delattre O, Bourdeaut F, Peuchmaur M. PHOX2B immunolabeling: a novel tool for the diagnosis of undifferentiated neuroblastomas among childhood small round blue-cell tumors. Am J Surg Pathol 36: 1141–1149, 2012.

    PubMed  Article  Google Scholar 

  92. Hata JL, Correa H, Krishnan C, Esbenshade AJ, Black JO, Chung DH, Mobley BC. Diagnostic utility of PHOX2B in primary and treated neuroblastoma and in neuroblastoma metastatic to the bone marrow. Arch Pathol Lab Med 139: 543–546, 2015.

    PubMed  Article  Google Scholar 

  93. Shawa H, Elsayes KM, Javadi S, Morani A, Williams MD, Lee JE, Waguespack SG, Busaidy NL, Vassilopoulou-Sellin R, Jimenez C, Habra MA. Adrenal ganglioneuroma: features and outcomes of 27 cases at a referral cancer centre. Clin Endocrinol (Oxf) 80: 342–347, 2014.

    CAS  Article  Google Scholar 

  94. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466–1477, 1993

    CAS  PubMed  Article  Google Scholar 

  95. Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D'Angio G, De Bernardi B, Evans AE, Favrot M, Freeman AI, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 6:1874–1881, 1988.

    CAS  PubMed  Article  Google Scholar 

  96. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD; INRG Task Force. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 27: 298–303, 2009.

    PubMed  PubMed Central  Article  Google Scholar 

  97. Lam KY, Lo CY. Composite pheochromocytoma-ganglioneuroma of the adrenal gland: an uncommon entity with distinctive clinicopathologic features. Endocr Pathol 1999;10: 343–352.

    PubMed  Article  Google Scholar 

  98. Comstock JM, Willmore-Payne C, Holden JA, Coffin CM. Composite pheochromocytoma: a clinicopathologic and molecular comparison with ordinary pheochromocytoma and neuroblastoma. Am J Clin Pathol 132:69–73, 2009.

    CAS  PubMed  Article  Google Scholar 

  99. Shawa H, Elsayes KM, Javadi S, Sircar K, Jimenez C, Habra MA. Clinical and radiologic features of pheochromocytoma/ganglioneuroma composite tumors: a case series with comparative analysis. Endocr Pract 20: 864–869, 2014.

    PubMed  Article  Google Scholar 

  100. Shida Y, Igawa T, Abe K, Hakariya T, Takehara K, Onita T, Sakai H. Composite pheochromocytoma of the adrenal gland: a case series. BMC Res Notes 8: 257, 2015.

    PubMed  PubMed Central  Article  Google Scholar 

  101. Loehry CA, Kingham JG, Whorwell PJ. Watery diarrhoea and hypokalaemia associated with a phaeochromocytoma. Postgrad Med J 51:416–419, 1975.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  102. Jiang J, Zhang L, Wu Z, Ai Z, Hou Y, Lu Z, Gao X. A rare case of watery diarrhea, hypokalemia and achlorhydria syndrome caused by pheochromocytoma. BMC Cancer 14: 553, 2014.

    PubMed  PubMed Central  Article  Google Scholar 

  103. Tischler AS, Dayal Y, Balogh K, Cohen RB, Connolly JL, Tallberg K. The distribution of immunoreactive chromogranins, S-100 protein, and vasoactive intestinal peptide in compound tumors of the adrenal medulla. Hum Pathol 18: 909–917, 1987.

    CAS  PubMed  Article  Google Scholar 

  104. Lam KY, Loong F, Shek TWH, Chu SM. Composite paraganglioma-ganglioneuroma of the urinary bladder: a cliniopathologic, immunohistochemical, and ultrastructural study of a case and review of the literature. Endocr Pathol 1998;9: 363–373.

    Article  Google Scholar 

  105. Monclair T, Ruud E, Holmstrøm H, Aagenæs I, Asplin M, Beiske K. Extra-adrenal composite phaeochromocytoma/neuroblastoma in a 15-month-old child. J Ped Surg Case Reports 3: 348e350, 2015.

    Google Scholar 

  106. Ohtsuki Y, Watanabe R, Okada Y, Matsuka Y, Lee GH, Furihata M. Composite paraganglioma and ganglioneuroma in the retroperitoneum: a case report. Med Mol Morphol 45: 168–172, 2012.

    PubMed  Article  Google Scholar 

  107. Ito H, Kurokawa T, Yokoyama O. Composite paraganglioma with ganglioneuroma in the retroperitoneal space. Int J Urol 17: 385–386, 2010.

    PubMed  Article  Google Scholar 

  108. Hirasaki S, Kanzaki H, Okuda M, Suzuki S, Fukuhara T, Hanaoka T. Composite paraganglioma-ganglioneuroma in the retroperitoneum. World J Surg Oncol 7: 81, 2009.

    PubMed  PubMed Central  Article  Google Scholar 

  109. Chen CH, Boag AH, Beiko DT, Siemens DR, Froese A, Isotalo PA. Composite paraganglioma-ganglioneuroma of the urinary bladder: a rare neoplasm causing hemodynamic crisis at tumour resection. Can Urol Assoc J 3: E45–E48, 2009.

    PubMed  PubMed Central  Article  Google Scholar 

  110. Usuda H, Emura I. Composite paraganglioma-ganglioneuroma of the urinary bladder. Pathol Int 55: 596–601, 2005.

    PubMed  Article  Google Scholar 

  111. Dundr P, Dudorkinová D, Povýsil C, Pesl M, Babjuk M, Dvorácek J, Zelinka T. Pigmented composite paraganglioma-ganglioneuroma of the urinary bladder. Pathol Res Pract 199:765–769, 2003.

    PubMed  Article  Google Scholar 

  112. Hu J, Wu J, Cai L, Jiang L, Lang Z, Qu G, Liu H, Yao W, Yu G. Retroperitoneal composite pheochromocytoma-ganglioneuroma: a case report and review of literature. Diagn Pathol 8: 63, 2013.

    PubMed  PubMed Central  Article  Google Scholar 

  113. Shankar GM, Chen L, Kim AH, Ross GL, Folkerth RD, Friedlander RM. Composite ganglioneuroma-paraganglioma of the filum terminale. J Neurosurg Spine 12: 709–713, 2010.

    PubMed  Article  Google Scholar 

  114. de Montpréville VT, Mussot S, Gharbi N, Dartevelle P, Dulmet E. Paraganglioma with ganglioneuromatous component located in the posterior mediastinum. Ann Diagn Pathol. 9: 110–114, 2005.

    PubMed  Article  Google Scholar 

  115. Armstrong R, Greenhalgh KL, Rattenberry E, Judd B, Shukla R, Losty PD, Maher ER. Succinate dehydrogenase subunit B (SDHB) gene deletion associated with a composite paraganglioma/neuroblastoma. J Med Genet 46: 215–216, 2009.

    CAS  PubMed  Article  Google Scholar 

  116. Fritzsche FR, Bode PK, Koch S, Frauenfelder T. Radiological and pathological findings of a metastatic composite paraganglioma with neuroblastoma in a man: a case report. J Med Case Rep 4: 374, 2010.

    PubMed  PubMed Central  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Alfred King-yin Lam.

Ethics declarations

Funding

None.

Conflict of Interest

The author declares that there is no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lam, A.Ky. Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours. Endocr Pathol 28, 213–227 (2017). https://doi.org/10.1007/s12022-017-9484-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12022-017-9484-5

Keywords

  • WHO
  • Adrenal
  • Tumour
  • Genetic
  • Pathology